Clinical trials
Nephropathy clinical trials
Below are recruiting nephropathy clinical trials, each written for real people, not researchers. We’re tracking 147 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06285279RecruitingPhase 1
CAR-T cell therapy for hard-to-treat autoimmune kidney diseases
This trial tests a new type of cell therapy called CAR-T cells that target two proteins (BCMA and CD19) to treat autoimmune kidney diseases that are not responding to standard treatments. The goal is to see if this therapy can help control the disease and improve kidney function.
Nanjing, JiangsuAges 18–65 - NCT06720532Recruiting
Kidney function in men with prostate cancer getting a new targeted radiation therapy
This study looks at how a targeted radiation therapy called 177Lu-PSMA affects kidney function in men with a type of advanced prostate cancer. It aims to understand risk factors to help guide safe treatment.
MunichAges 18 years+ - NCT06792799RecruitingEarly Phase 1
CAR-NK cells for B-cell autoimmune diseases
This early phase trial tests a new treatment made from immune cells (CAR-NK cells) that target and destroy overactive B cells. It may help people with lupus, certain kidney diseases, or nephrotic syndrome that hasn't responded to standard therapies.
Hangzhou, ZhejiangAges 3 years+ - NCT06837181Recruiting
Understanding diabetes complications in cystic fibrosis
This study looks at how long-term diabetes affects people with cystic fibrosis. It helps researchers understand complications and improve care.
Birmingham, AlabamaAges 12 years+ - NCT06846034Recruiting
How low oxygen affects kidney blood flow
This study tests how low oxygen levels affect blood flow in the kidneys. It includes healthy people, people with type 2 diabetes, and those with diabetes plus kidney disease to see if their kidneys respond differently.
PoitiersAges 18–75 - NCT06994845RecruitingPhase 3
Testing iptacopan for children with IgA nephropathy
This study tests a new medicine called iptacopan to see if it helps children with IgA nephropathy (a kidney disease). Kids who join will receive the study treatment and be monitored for safety and effectiveness.
Aurora, ColoradoAges 2–18 - NCT07022418RecruitingPhase 2
Formoterol for diabetic kidney disease
This trial tests if a drug called formoterol (usually used for asthma) can help protect the kidneys in people with type 2 diabetes and early-to-moderate kidney disease. It may offer a new way to slow kidney damage.
Charleston, South CarolinaAges 18–75 - NCT07038382RecruitingPhase 2
Study of HLX79 with Rituximab for Active Kidney Disease
This trial tests a new drug called HLX79 (a human sialidase fusion protein) combined with rituximab, compared to a placebo, for people with active membranous nephropathy (a kidney disease). It aims to see if this combination can reduce protein in the urine and improve kidney function.
BeijingAges 18–75 - NCT07072468RecruitingPhase 2
Test of a gel for nerve pain after chemotherapy
This study tests a new gel (VMD-3866) applied to the skin to treat moderate nerve pain, numbness, or tingling caused by previous chemotherapy. It aims to see if the gel can safely reduce pain for people whose symptoms have been stable for at least 8 weeks.
London, UKAges 18–80 - NCT07246265Recruiting
Morphine clearance study for sickle cell crisis in ICU
This study looks at how the body clears morphine in adults with sickle cell disease who are in the intensive care unit (ICU) for a pain crisis or acute chest syndrome and are receiving morphine through a patient-controlled analgesia (PCA) pump. The goal is to understand how kidney function affects morphine breakdown.
Tours, FranceAges 18 years+ - NCT07256613Recruiting
Gum treatment and kidney health in type 2 diabetes
This study tests whether non-surgical gum treatment can help improve kidney function in people with type 2 diabetes and gum disease. If you have both conditions and your kidneys are still working well, this treatment may help prevent further kidney damage.
Karachi, SindhAges 30–65 - NCT07295808Recruiting
Study of IgA antibodies in kidney disease
This study looks at a specific type of antibody called IgA in patients with certain kidney diseases. It aims to understand which IgA antibodies cause kidney damage, which could help develop better treatments.
LimogesAges 18 years+ - NCT07305116RecruitingPhase 1
CAR T-cell therapy for autoimmune diseases
This trial tests a new immune therapy called CAR T-cells that target two proteins (CD19 and BCMA) to treat autoimmune diseases like lupus, nephrotic syndrome, and others. It is for people whose standard treatments have not worked well enough.
Hangzhou, ZhejiangAges 3 years+ - NCT07390123RecruitingPhase 3
Study of HSK39297 for IgA Nephropathy (IgAN)
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
Huangshan City, AnhuiAges 18 years+ - NCT01531257Recruiting
Monitoring genes and health after kidney transplant
This study follows people who are getting a kidney transplant (first or later) to better understand how the body recovers, using health tracking and “gene/protein” (proteogenomic) information. It may help doctors predict complications and improve care after transplant.
Chicago, IllinoisAges 18 years+ - NCT01209000Recruiting
Study for children with new kidney protein loss
This study is for children (and some newly diagnosed patients) who have nephrotic syndrome—kidneys leaking a lot of protein. It aims to better understand the kidney condition (sometimes using biopsy) and support future care decisions.
Los Angeles, CaliforniaAges Up to 80 years - NCT00977977RecruitingPhase 2
Rituximab plus cyclosporine for membranous kidney disease
This trial tests whether rituximab (an immune-targeting medicine) plus cyclosporine (another immune medicine) can better control protein leakage in the urine for people with idiopathic membranous nephropathy. It may help reduce long-lasting kidney damage risk when standard treatments like ACE inhibitor or ARB don’t control the protein level.
Bethesda, MarylandAges 18–90 - NCT02132741Recruiting
Eye imaging study in people with kidney disease
This study uses a painless eye scan to learn more about how kidney disease may be linked to eye changes. It may help improve understanding and future care for people with chronic kidney disease and/or high blood pressure.
Edinburgh, MidlothianAges 18–80 - NCT02818192Recruiting
Kid-focused study to track kidney issues in type 2 diabetes
This study follows young people with type 2 diabetes to better understand risks for kidney problems over time. It may help researchers find earlier warning signs and improve care for adolescents living with type 2 diabetes.
Winnipeg, ManitobaAges 10–18 - NCT07507201RecruitingEarly Phase 1
Car-T cells for autoimmune diseases like lupus
This trial tests whether specially-engineered immune cells (CAR-T cells) can help people with certain autoimmune diseases that haven't gotten better with standard treatments. The cells are designed to target and remove faulty B cells that are causing the immune system to attack the body.
Hangzhou, ZhejiangAges 3 years+ - NCT07516964Recruiting
Studying autoimmune kidney disease in children and adults
This study collects medical information and samples from patients with podocytopathy—a type of autoimmune kidney disease that causes protein leakage into urine. Researchers will analyze your medical records and any blood or kidney tissue samples you've already had to better understand the disease and find better treatments.
Rochester, MinnesotaAges birth–99 years - NCT07561957Recruiting
Smartphone app to help manage chronic kidney disease
This study tests a smartphone app designed to help people with chronic kidney disease (CKD)—a condition where the kidneys don't filter blood as well as they should—follow the latest medical guidelines. The app aims to make it easier for younger adults to stay on top of their kidney health and treatment.
DublinAges 16–30 - NCT07585981Recruiting
Budesonide capsules for IgA kidney disease
This trial tests whether a special steroid capsule called budesonide can help treat IgA nephropathy, a kidney disease where your immune system damages the kidneys. You would take this medication along with standard care to see if it slows kidney damage and reduces protein in your urine.
BeijingAges 18 years+ - NCT07586267RecruitingEarly Phase 1
CAR-T cell therapy for autoimmune blood diseases
This early-stage trial tests a new type of cell therapy (CAR-T cells) designed to treat severe autoimmune diseases where the immune system attacks the body's own organs. The therapy targets specific immune cells (B cells) that may be causing the disease. It may help patients who haven't improved with standard treatments or can't tolerate them.
Hangzhou, ZhejiangAges 3 years+
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for nephropathy?
- Yes. Clin2 currently lists 147 recruiting nephropathy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a nephropathy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a nephropathy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.